No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62).
Juan M TiraboschiJhon RojasHenrik ZetterbergKaj BlennowJordi NiuboJohanna M GostnerAntonio Navarro-AlcarazCamila PiattiDietmar FuchsMagnus GisslénRaul Rigo-BonninEsteban MartinezDaniel PodzamczerPublished in: The Journal of infectious diseases (2022)
A major concern of human immunodeficiency virus (HIV) dual therapy is a potentially lower efficacy in viral reservoirs, especially in the central nervous system (CNS). We evaluated HIV RNA, neuronal injury, and inflammatory biomarkers and dolutegravir (DTG) exposure in cerebrospinal fluid (CSF) in patients switching to DTG plus lamivudine (3TC). All participants maintained viral suppression in plasma and CSF at week 48. We observed no increase in CSF markers of inflammation or neuronal injury. Median (interquartile range) total and unbound DTG in CSF were 7.3 (5.9-8.4) and 1.7 (1.2-1.9) ng/mL, respectively. DTG+3TC may maintain viral control without changes in inflammatory/injury markers within the CNS reservoir.
Keyphrases
- human immunodeficiency virus
- antiretroviral therapy
- hiv aids
- hiv infected patients
- hiv infected
- cerebrospinal fluid
- hiv positive
- hepatitis c virus
- end stage renal disease
- ejection fraction
- sars cov
- oxidative stress
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- bone marrow
- randomized controlled trial
- prognostic factors
- hiv testing
- mesenchymal stem cells
- subarachnoid hemorrhage
- network analysis
- study protocol
- patient reported outcomes